Public database gets screening libraries

Ten screening libraries from ChemBridge are now available to researchers via the Collaborative Drug Discovery (CDD) public access database. CDD subscribers can access the data from private groups, mining the libraries--which include biological and chemical data from vendors and researchers, as well as scientific literature and patent resources--using their own private tools to identify compounds of interest within the ChemBridge datasets.

Among the libraries that ChemBridge has made available is DIVERSet, a dataset of 50,000 small molecules spanning the pharmacophore space. CNS-Set--which contains 56,000 molecules having an increased probability of blood/brain barrier penetration--is also now available, as well as eight other ChemBridge libraries. In total, some 600,000 molecules have been added to the CDD Database. 

The CDD database previously contained more than a million compounds. ChemBridge joins co-contributors from the academic, non-profit, and industry sectors. According to an announcement, thousands of researchers around the world access the data sets and software. Registration is free for read-only access to the new and all public CDD data sets. Read/write access is available following a free trial with full commercial access.

- here's the announcement
- sign up here for public access 

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.